Advertisement


David Palma, MD, PhD, on Oligometastatic Tumors: Results From the SABR-COMET Trial

2018 ASTRO Annual Meeting

Advertisement

David Palma, MD, PhD, of the London Health Sciences Centre, discusses study findings on improvement in survival following stereotactic ablative radiation for oligometastatic tumors (Presentation 5 in PL 01).



Related Videos

Head and Neck Cancer
Symptom Management

Thomas Galloway, MD, on Oropharyngeal Cancer: Improving Outcomes and Reducing Toxicity

Thomas Galloway, MD, of Fox Chase Cancer Center, summarizes a session on head and neck cancer that included findings on reducing oral mucositis, improving quality of life with deintensified chemoradiotherapy, and the costs of dose de-escalation (Scientific Session 31).

Prostate Cancer

Howard M. Sandler, MD, on Prostate Cancer: Prospective Trials Update

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses a session on data from several long-term studies on localized disease, including optimal sequencing of radiation and androgen-deprivation therapy; the efficacy and toxicity of SBRT; conventional vs hypofractionated radiation therapy; and dose escalation (Scientific Symposium 08).

Prostate Cancer

Howard M. Sandler, MD, on Localized Prostate Cancer: Radiation Therapy Guidelines

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, summarizes a session he moderated that included discussion of an ASTRO, ASCO, and AUA guideline; indications and dose fractionation; treatment volumes; and the use of IGRT and IMRT (Panel 03).

Lung Cancer

Daniel R. Gomez, MD, on NSCLC: Findings From a Phase II Treatment Trial

Daniel R. Gomez, MD, of The University of Texas MD Anderson Cancer Center, discusses the final results of a phase II study on local consolidative therapy, which improved overall survival compared with maintenance therapy and observation in oligometastatic non–small cell lung cancer (Abstract LBA3).

Prostate Cancer

Daniel E. Spratt, MD, on Prostate Cancer in African American Men: Results of a Meta-analysis

Daniel E. Spratt, MD, of the University of Michigan, discusses a large-scale gene-expression analysis and meta-analysis of RTOG trials on androgen receptor activity and radiotherapeutic sensitivity in African American men with prostate cancer (Abstract 4).

Advertisement

Advertisement



Advertisement